Century Therapeutics Announces Election of Directors and Increase in Authorized Common Stock

On June 11, 2026, Century Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where several key proposals were approved. Stockholders elected Alessandro Riva, M.D., and Han Lee, Ph.D., M.B.A., as Class II directors to serve until the 2029 Annual Meeting. Additionally, the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the 2026 fiscal year was ratified. A significant outcome of the meeting was the approval of an amendment to the Company’s Second Amended and Restated Certificate of Incorporation. This amendment increases the number of authorized shares of common stock from 300,000,000 to 450,000,000. The total authorized capital stock now stands at 460,000,000 shares, including 10,000,000 shares of preferred stock. The certificate of amendment was filed with the Secretary of State of Delaware on June 11, 2026, and became effective on June 12, 2026. The meeting also approved a proposal for adjournment if necessary, though it was not required given the approval of the share increase.